SURG (SurgePays, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by SURG officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-05 | David Allen May | Director | Buy | — | — |
| 2026-06-03 | Kevin Brian Cox | CEO & Chairman | A | — | — |
| 2026-04-07 | Kevin Brian Cox | CEO & Chairman | MIXED | — | — |
| 2026-01-05 | Anthony George Evers | Chief Financial Officer | A | — | — |
| 2025-12-11 | David Allen May | Director | Buy | — | — |
| 2025-06-10 | David Allen May | Director | Sell | — | — |
| 2025-05-27 | Laurie Weisberg | Director | A | — | — |
| 2025-05-27 | DAVID N KEYS | Director | A | — | — |
| 2025-05-27 | Richard Earl Schurfeld | Director | A | — | — |
| 2025-05-19 | Kevin Brian Cox | CEO and Chairman of Board | Buy | — | — |
| 2024-12-04 | Kevin Brian Cox | CEO and Chairman of Board | Sell | — | — |
| 2024-12-04 | Anthony George Evers | Chief Financial Officer | Sell | — | — |
| 2024-11-25 | Laurie Weisberg | Director | Buy | — | — |
| 2024-11-20 | Richard Earl Schurfeld | Director | Buy | — | — |
| 2024-11-15 | Anthony George Evers | Chief Financial Officer | Sell | — | — |
| 2024-11-15 | Kevin Brian Cox | CEO and Chairman of Board | Sell | — | — |
| 2015-10-15 | Robert H Blankemeyer | Director | D | — | — |
| 2015-10-15 | Jason Stroisch | VP-Marketing & Technology | MIXED | — | — |
| 2015-10-15 | David Graeme Thomas | Director | U | — | — |
| 2015-10-15 | Michael Fanning | VP of Domestic Sales | MIXED | — | — |
| 2015-10-15 | PAMELA G BOONE | EVP & Chief Financial Officer | MIXED | — | — |
| 2015-10-15 | David M Hable | President and CEO | MIXED | — | — |
| 2015-10-15 | Lawrence C Cardinale | Director | U | — | — |
| 2015-10-15 | JUANITA H HINSHAW | Director | U | — | — |
| 2015-09-21 | Lawrence C Cardinale | Director | M | — | — |
| 2015-09-21 | JUANITA H HINSHAW | Director | M | — | — |
| 2015-01-02 | Michael Fanning | VP of Domestic Sales | Sell | — | — |
| 2014-12-29 | Michael Fanning | VP of Domestic Sales | Sell | — | — |
| 2014-12-17 | PAMELA G BOONE | EVP & Chief Financial Officer | A | — | — |
| 2014-12-17 | Jason Stroisch | VP-Marketing & Technology | A | — | — |
| 2014-12-17 | David M Hable | President and CEO | A | — | — |
| 2014-12-17 | Michael Fanning | VP of Domestic Sales | A | — | — |
| 2014-12-16 | Robert H Blankemeyer | Director | A | — | — |
| 2014-12-16 | David Graeme Thomas | Director | A | — | — |
| 2014-12-16 | Lawrence C Cardinale | Director | A | — | — |
| 2014-12-16 | JUANITA H HINSHAW | Director | A | — | — |
| 2014-10-21 | David Graeme Thomas | Director | Buy | — | — |
| 2014-03-27 | David M Hable | President and CEO | Buy | — | — |
| 2014-03-24 | David Graeme Thomas | Director | Buy | — | — |
| 2014-01-14 | GUY R GUARCH | Director | M | — | — |
| 2014-01-07 | Michael Fanning | VP of Domestic Sales | Sell | — | — |
| 2014-01-06 | David Graeme Thomas | Director | Buy | — | — |
| 2013-12-23 | PAMELA G BOONE | EVP & Chief Financial Officer | A | — | — |
| 2013-12-23 | Lawrence C Cardinale | Director | M | — | — |
| 2013-12-23 | Jason Stroisch | VP-Marketing & Technology | A | — | — |
| 2013-12-23 | Michael Fanning | VP of Domestic Sales | A | — | — |
| 2013-12-23 | David M Hable | President and CEO | A | — | — |
| 2013-12-19 | ROBERT H DICK | Director | M | — | — |
| 2013-12-17 | Lawrence C Cardinale | Director | A | — | — |
| 2013-12-17 | ROBERT H DICK | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | CEO & Chairman | 2,070,745 | — |
| — | Chief Financial Officer | 414,924 | — |
| — | Director | 121,789 | — |
| — | Director | 97,501 | — |
| — | Director | 67,043 | — |
| — | Director | 57,809 | — |
| — | EVP & Chief Operating Officer | 30,154 | — |
| — | EVP & Chief Scientific Officer | 10,884 | — |
| — | Director | 6,734 | — |
| — | President and CEO | 2,164 | — |
| — | Director | 860 | — |
| — | EVP & Chief Financial Officer | 829 | — |
| — | VP-Marketing & Technology | 681 | — |
| — | VP of Domestic Sales | 614 | — |
| — | Director | 320 | — |
| — | EVP Marketing & Sales | 116 | — |
| — | Director | 90 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the SURG quote page; the site-wide leaderboard is on the insider transactions hub.